Delcath Systems, Inc. is a medical technology company based in New York, specializing in the development of innovative therapies for the treatment of cancer. The company focuses on its proprietary delivery system, which allows for targeted administration of chemotherapeutic agents directly to tumors while minimizing systemic exposure. Delcath's technology aims to improve patient outcomes in oncology by enhancing the efficacy of treatment while reducing side effects, positioning the company as a key player in the field of interventional oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#419 in New York, NY

#1,006 in New York

#17,138 in US

#32,663 in the World

New York, NY, United States of America

Delcath Systems, Inc.

Forward Citations = 698

9 inventors:

William M Appling (12 out of 68 patents)

Daniel Stephen Johnston (9 out of 11 patents)

Jacques Chammas (7 out of 18 patents)

4. Samantha J Barton (7 out of 7 patents)

5. Matthew G Barton (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Delcath Systems, Inc.. Retrieved from https://idiyas.com/company/delcath-systems

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

8 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]